What is Zymeworks's ZW191 — R&D?

Zymeworks (ZYME) reported ZW191 — R&D of $3.03M in Q1 2026.

What does ZW191 — R&D mean?

This metric represents the total investment allocated to the research and development activities specifically associated with the ZW191 clinical candidate. It captures the resources dedicated to advancing this specific therapeutic asset through its various stages of discovery and clinical evaluation. Tracking this investment helps stakeholders assess the company's commitment to prioritizing this asset within its broader biopharmaceutical pipeline.

Zymeworks ZYME ZW191 — R&D

Other product segments

Expense for other preclinical and research programs

$6.37M+226%

Zanidatamab

$4.62M-58.7%

ZW220

$2.14M+439%

ZW251

$2.03M+1,085%

ZW171

$1.83M-31.5%

Similar metrics at other companies

NRIXNX-1607 — R&D

$1.19M-39.4%

AXSMAZD7325 — Research And Development Expense

$2.3M—

SRRKRD Expense Srk181 — Research And Development Expense

$36K-96.8%

ARQTOther program costs — R&D

$95K-92.0%

IRONDISC Zero Nine Seven Four — Research And Development Expense

$8.11M+32.5%

INSMINS1148 — R&D

$10M—

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.79B+125%

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's zw191 — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's ZW191 — R&D?: Zymeworks (ZYME) reported ZW191 — R&D of $3.03M in Q1 2026.
What does ZW191 — R&D mean?: This metric represents the total investment allocated to the research and development activities specifically associated with the ZW191 clinical candidate. It captures the resources dedicated to advancing this specific therapeutic asset through its various stages of discovery and clinical evaluation. Tracking this investment helps stakeholders assess the company's commitment to prioritizing this asset within its broader biopharmaceutical pipeline.